Microbot Medical receives FDA 510(k) clearance for LIBERTY Endovascular Robotic System

Microbot Medical Inc.

FDA 510(k) clearance for LIBERTY System, first single-use remotely operated robotic system for peripheral endovascular procedures.
Pivotal study showed 100% robotic navigation success and zero device-related adverse events; 92% relative reduction in physician radiation exposure.
Plans to commence commercialization in Q4 2025; initial U.S. addressable market of ~2.5M peripheral vascular procedures annually.
CEO Harel Gadot to present at H.C. Wainwright Annual Investor Conference on Sept 9, 2025 at 9 AM ET.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.